AFP and hepatocellular carcinoma: Among HCC patients, acetylcarnitine showed a discriminative accuracy of > 70% for those with normal AFP (AFP < 15 mg/L), suggesting that acetylcarnitine may be served as a sensitive and specific biomarker, in complementary to AFP, for monitoring the development of HCC.